An open-label extension study of long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

An open-label extension study of long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms INPULSIS-ON
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Jun 2017 This trial has been completed in Germany.
    • 24 May 2017 Results (n=734) of subgroup analysis assessing the effect of nintedanib dose on FVC decline in INPULSIS-ON trial, presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of subgroup analysis from INPULSIS -ON presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top